Rimonabant Sanofi-Synthélabo.
Copyright policy )Rimonabant Sanofi-Synthélabo.
Rimonabant, an antagonist of central cannabinoid type 1 (CB1) receptors, is being developed by Sanofi-Synthélabo for the potential treatment of obesity and as a potential smoking cessation agent. Phase III trials were initiated for obesity in August 2001 and were ongoing in September 2003. By September 2002, the compound had entered phase III trials for smoking cessation, and these trials were ongoing in September 2003.
- University of Alabama at Birmingham United States
Clinical Trials as Topic, Structure-Activity Relationship, Piperidines, Receptor, Cannabinoid, CB1, Appetite Depressants, Potassium Channel Blockers, Animals, Humans, Pyrazoles, Smoking Cessation, Anti-Obesity Agents, Obesity, Rimonabant, Antipsychotic Agents
Clinical Trials as Topic, Structure-Activity Relationship, Piperidines, Receptor, Cannabinoid, CB1, Appetite Depressants, Potassium Channel Blockers, Animals, Humans, Pyrazoles, Smoking Cessation, Anti-Obesity Agents, Obesity, Rimonabant, Antipsychotic Agents
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).62 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 1%
Citations provided by BIP!Popularity provided by BIP!